Other experts have suggested royalties comprising the marginal cost of production plus 5 per cent of the compulsory licensee’s selling price, see Reichman, UNCTAD paper, p. 20, quoting A. Engelberg. A general royalty rate of 4 per cent is suggested, as representing the average royalty rate for pharmaceutical products in the United States market. Second, the general royalty rate is adjusted according to each country’s capacity to pay, as reflected in relative per capita income or, where a disease affects a country in an unusually high degree, the relative income per person needing treatment.